Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30728286.
- Also identified by DOI 10.1126/scitranslmed.aav4810.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with immune checkpoint inhibitors targeting programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) is effective in many cancer types. Tumors harboring specific mutations modulate antitumor immune responses through the PD-1/PD-L1 axis, and this should be taken into account when designing rational combinatory treatments.
Medical subject headings
- B7-H1 Antigen
- Neoplasms